Improving MHC-associated peptide sequencing approaches for tumor antigen identification

Harnessing the immune system to treat cancer is a relatively new therapeutic avenue, and therapies that target neoantigens, either directly or indirectly, have shown strong antitumor efficacy in select patients. The goal is to find ways to help more patients benefit from these revolutionary treatments.
Listen to Dr. Julie Rumble discuss some of the key considerations for planning your immunopeptidome profiling experiment, from antibody choice to biological input and mass spec output. Optimization of these experiments will help to drive better peptide sequencing and increased neoantigen identification. Immunopeptidome profiling of MHC can be a powerful tool for empirically determining what peptides may be presented as possible targets for immune-mediated tumor destruction.
Hosted by Hanson Wade as part of the 5th Annual Neoantigen Based Therapies Summit.
Learn More About Cayman Chemical's Immunopeptidome Profiling Services: www.caymanchem...